{"id":"bevacizumab-containing-regimen","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Hypertension"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Headache"},{"rate":"5-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved by binding to VEGF-A, preventing its interaction with its receptor, and subsequently inhibiting the formation of new blood vessels that tumors need to grow and metastasize. This mechanism is particularly effective in treating various types of cancer.","oneSentence":"Bevacizumab-containing regimens work by inhibiting angiogenesis through the blockade of vascular endothelial growth factor A (VEGF-A).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:15.590Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Non-small cell lung cancer"},{"name":"Breast cancer"},{"name":"Glioblastoma"},{"name":"Renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT07059494","phase":"PHASE4","title":"Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-06","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT07448480","phase":"","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma","enrollment":1000},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT03280563","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-22","conditions":"Breast Neoplasms","enrollment":144},{"nctId":"NCT05104567","phase":"PHASE2","title":"A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-12-09","conditions":"Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma","enrollment":138},{"nctId":"NCT07106034","phase":"PHASE2","title":"Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pudong Hospital","startDate":"2025-08-31","conditions":"Advanced Colorectal Cancer","enrollment":32},{"nctId":"NCT03475004","phase":"PHASE2","title":"Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2018-09-17","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":53},{"nctId":"NCT02743221","phase":"PHASE2","title":"A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2016-04-29","conditions":"Metastatic Colorectal Cancer","enrollment":154},{"nctId":"NCT03485027","phase":"PHASE2","title":"Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2018-01-24","conditions":"Metastatic Colorectal Cancer, Chemotherapy Effect","enrollment":43},{"nctId":"NCT05797883","phase":"PHASE2","title":"FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2022-08-01","conditions":"Unresectable or Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT03020602","phase":"PHASE1","title":"BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab","status":"COMPLETED","sponsor":"Seema Nagpal","startDate":"2017-01-04","conditions":"Gliosarcoma, Recurrent Glioblastoma, Astrocytoma of Brain","enrollment":12},{"nctId":"NCT02226289","phase":"PHASE2","title":"Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2020-09","conditions":"Neoplasm, Colorectal Cancer, Metastatic Neoplasm","enrollment":46},{"nctId":"NCT02540161","phase":"PHASE2","title":"Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Annick Desjardins","startDate":"2016-02-01","conditions":"Malignant Glioma","enrollment":43},{"nctId":"NCT01248962","phase":"PHASE2","title":"Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-11","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":146},{"nctId":"NCT02664961","phase":"PHASE2","title":"Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)","status":"TERMINATED","sponsor":"Tracon Pharmaceuticals Inc.","startDate":"2016-03","conditions":"Gestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor","enrollment":3},{"nctId":"NCT01112527","phase":"PHASE2","title":"PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-04","conditions":"Glioblastoma, GBM, Glioblastoma Multiforme","enrollment":58},{"nctId":"NCT00675259","phase":"PHASE2","title":"Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2008-07","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT02047214","phase":"PHASE2","title":"Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy","status":"TERMINATED","sponsor":"Cortice Biosciences, Inc.","startDate":"2014-01","conditions":"Glioblastoma Multiforme","enrollment":17},{"nctId":"NCT02831842","phase":"","title":"A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-06-09","conditions":"Colorectal Cancer","enrollment":4278},{"nctId":"NCT02829008","phase":"PHASE2","title":"Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2016-04","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT01131078","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-06","conditions":"Colorectal Cancer","enrollment":306},{"nctId":"NCT00531960","phase":"PHASE2","title":"A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Non-Small Cell Lung Cancer","enrollment":124},{"nctId":"NCT00615056","phase":"PHASE2","title":"A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-03","conditions":"Colorectal Neoplasms","enrollment":171},{"nctId":"NCT00889343","phase":"PHASE2","title":"Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","startDate":"2009-03","conditions":"Colorectal Neoplasms","enrollment":101}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avastin"],"phase":"phase_2","status":"active","brandName":"Bevacizumab-containing regimen","genericName":"Bevacizumab-containing regimen","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab-containing regimens work by inhibiting angiogenesis through the blockade of vascular endothelial growth factor A (VEGF-A). Used for Metastatic colorectal cancer, Non-small cell lung cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}